CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 52 enrolled
Drug / intervention
Lithium +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05618587
NCT05618587Phase 2Completed
CompareCT.gov

Effect of Low-dose Lithium Therapy on Long COVID Symptoms: a Randomized Controlled Trial.

State University of New York at Buffalo·interventional·Posted Nov 16, 2022·Updated Mar 5, 2025

In Brief

A Phase 2 clinical trial evaluating Lithium and Placebo for Long COVID. Completed, enrolled 52 participants across 1 site.

Detailed Summary

This study will assess low-dose lithium's effects on several different symptoms experienced by long COVID patients.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLong COVID
CountriesUnited States
CollaboratorsNational Center for Advancing Translational Sciences (NCATS)

Timeline

Phase 2CompletedFinished
2023202420252026
First PostedNov 16, 2022
Enrollment StartNov 28, 2022
Primary CompletionJul 21, 2023
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 3.6 years ago

Interventions

Lithiumdrug

Lithium has multiple mechanisms of action including anti-inflammatory actions, which may be relevant for treating long COVID.

Placebodrug

Inactive pill